Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

• Main Authors: Kanters, T.A, Hoogenboom-Plug, I, Rutten-Van Mölken, M.P, Redekop, W.K, Van Der Ploeg, A.T, Hakkaart, L
• Other Authors: SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
• Format: Article
• Published: 2020
• Subjects: recombinant glucan 1,4 alpha glucosidase; alpha glucosidase; GAA protein, human; adolescent; adult; article; child; cost effectiveness analysis; enzyme replacement; female; glycogen storage disease type 2; health care cost; health care utilization; hospital cost; human; life expectancy; major clinical study; male; middle aged; preschool child; quality adjusted life year; quality of life; school child; survival; teaching; young adult; cost benefit analysis; drug cost; economics; Glycogen Storage Disease Type II; infant; newborn; pathophysiology; alpha-Glucosidases; Cost-Benefit Analysis; Drug Costs; Enzyme Replacement Therapy; Humans; Infant; Infant, Newborn; Patient Simulation; Quality of Life
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181757
• Institution: National University of Singapore

10.1186/1750-1172-9-75